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Who gets a Mammogram amongst European women aged 50-69 years and why are 








On the basis of the Survey of Health, Ageing, and Retirement (SHARE), we analyse the 
determinants of who engages in mammography screening focusing on European women aged 
50-69 years. A special emphasis is put on the measurement error of subjective life expectancy 
and on the measurement and impact of physician quality. Our main findings are that physician 
quality, better education, having a partner, younger age and better health are associated with 
higher  rates  of  receipt.  The  impact  of  subjective  life-expectancy  on  screening  decision 
substantially increases after taking measurement error into account. In light of the enormous 
differences  in  mammography  screening  rates  between  the  European  countries  that  can  be 
detected even if several individual characteristics are taken into account, we explore in a 
second step the causes of these screening differences using newly available data from the 
SHARELIFE. The results reveal that in countries with low screening rates (e.g. Denmark, 
Greece and Poland) many reasons (financial restrictions, time costs, access barriers, lack of 
information, “not usual” and low perceived benefits of screening) are significant predictors of 
not receiving a mammogram. In contrast in countries with high screening rates such as the 
Netherlands  only  beliefs  regarding  the  benefits  of  mammograms  (“Not  considered  to  be 
necessary”) and the cause “Not usual to get this type of care” seem to be important screening 
barriers. 
 
JEL-Classification: C 26, I 11, I 18,  
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O´Donnell, Jürgen Maurer, Kai Riewe, Dirk Sauerland, Hendrik Schmitz and participants in the annual conferences of the 
“Verein für Socialpolitik” and the “Deutsche Gesellschaft für Gesundheitsökonomie” for their comments. This paper uses 
data from SHARELIFE release 1, as of November 24th 2010 or SHARE release 2.3.1, as of July 29th 2010. The SHARE 
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QLK6-CT-2001-  00360  in  the  thematic  programme  Quality  of  Life),  through  the  6th  framework  programme  (projects 
SHARE-I3,  RII-CT-  2006-062193,  COMPARE,  CIT5-CT-2005-028857,  and  SHARELIFE,  CIT4-CT-2006-028812)  and 
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U.S. National Institute on Aging (U01 AG09740-13S2, P01 AG005842, P01 AG08291, P30 AG12815, Y1-AG-4553-01 and 
OGHA 04-064, IAG BSR06-11, R21 AG025169) as well as from various national sources is gratefully acknowledged (see 
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Breast  Cancer  is  the  most  common  cause  of  cancer  death  in  the  member  states  of  the 
European  Union  (COM  2008).  According  to  estimates  of  incidence  and  mortality  by  the 
International Agency for Research on Cancer (IARC), there were 331,000 new cases and 
90,000 deaths due to breast cancer in the EU in 2006 (COM 2008). Breast cancer accounts for 
almost one out of three (30 per cent) new cancer cases and one out of six (17 per cent) cancer 
deaths. One in nine women gets breast cancer at some point in her life and one in thirty 
perishes  as  a  consequence  of  the  disease  (OECD  2009).  Due  to  demographic  trends, 
significantly more women per capita will be confronted with this disease in the future (Ferlay 
et al. 2007). Moreover breast cancer is associated with high costs for national health care. 
Overall spending for breast cancer typically amounts to about 0.5-0.6 per cent of the total 
health care expenditure of developed countries (OECD 2009). 
Breast cancer takes years to develop. At the onset of the disease, most breast cancers cause no 
symptoms. As long as cancer has not metastasized, i.e. that has not moved to the lymph 
system or to other organs of the body, patients have a five-year survival rate of 96 per cent. If 
the cancer has spread to the nearby lymph nodes, the rate drops down to 81 per cent. Women 
whose breast cancer has metastasized to other organs of the body have a five-year survival 
rate of 21 percent (US Department of Health and Human Services 2002).  
A mammogram screening is the best tool available for detecting breast cancer in the early 
stage, i.e. before symptoms appear. Mammography can detect a breast lump before it can be 
palpated; it can save live by detecting breast cancer in the earliest stage. For women aged 50-
69, mammography has been shown to lower the risk of dying from breast cancer by 35 per 
cent (Fang, Wang 2010). Moreover it has shown to be highly cost-effective for women in this 
age group (Moore et al. 2009). In light of the evidence available, the International Agency for 
Research  on  Cancer  expert  working  group  (IARC  Working  Group  2002)  advises  that 
mammography  screening should be offered as a public health policy directed to women aged 
50–69 every two years in order to reduce the risk of death from breast cancer. EU guidelines 
(European  Commission  2006)  promote  a  target  screening  rate  of  at  least  75  per  cent  of 
eligible  women  in  European  countries.  Even  though  mammography  is  officially 
recommended both on the national and European level, screening rates in most European   4 
countries remain far from 100 percent.
2 For example, in the Slovak Republic only around 20 
per  cent  of  women  aged  50-69  are  screened  annually  (OECD  2009).  Correspondingly, 
increasing mammography for women aged 50-69 is an important public health goal in Europe 
(Com 2008).  
 
There exists a considerable amount of empirical and theoretical research in health economics 
on  the  predictors  of  screening  and  preventive  behaviour.  Theoretical  economic  models 
include those of Grossman (1972), Cropper (1977), Giuffrida and Gravelle (1998), Byrne and 
Thompson  (2001),  Howard  (2005)  or  Fang  and  Wang  (2010).  Jepson  et  al.  (2000)  and 
Schueler et al. (2008) provide good reviews of the empirical literature on determinants of 
mammography screening uptake and recommendations for increasing uptake. Although the 
literature on factors associated with mammography screening is abundant, the reasons for 
underparticipation  remain  unclear,  because  empirical  results  are  inconclusive  and  still 
incomplete. Identifying the reasons behind lower screening rates is of high importance, since 
screening is  a crucial first step in the process  of early detection and treatment. Once the 
disease is detected, medical providers and the health care system have a major influence in 
what is done (Lairson, Chan and Newmark 2005).  
 
The  purposes  of  this  paper  are  twofold:    First  we  conduct  an  empirical  analysis  of  the 
determinants  (“Analysis  of  Screening  Determinants”)  of  participation  in  mammography 
screening. The analysis focuses on European women aged 50-69. The data base used is the 
first and second wave of the Survey of Health Aging and Retirement in Europe (SHARE). 
The first part of the analysis reveals some important and in empirical research so far widely 
neglected impact factors of mammography screening. However, it will also show that large 
differences in mammography screening rates remain between different European countries 
even after taking several individual characteristics into account. Therefore, the second aim of 
this paper is to identify the causes of screening differences between the European countries 
(“Analysis  of  Country  Differences”)  by  exploring  differences  between  countries  in  the 
reasons for not undertaking mammograms. With respect to this second aim, we analyse newly 
available  data  from  the  third  wave  of  the  SHARE-questionnaire  (“SHARELIFE”). 
SHARELIFE directly asks women for the reasons why they had never had, or stopped having 
mammograms done regularly focusing on perceived benefits, information issues, financial 
                                                 
2 There is serious controversy regarding the effectiveness and cost-effectiveness of mammography screening especially for 
women younger than 50 years and older than 70 years. Thus we focus on women aged 50-69 years.    5 
restrictions, time costs and availability of mammography services. This part of the analysis 
will disclose high differences in these factors between European countries. 
 
In  the  ”Analysis  of  Screening  Determinants”  the  impact  of  physician  quality  and  life 
expectancy  on  screening  decisions  will  be  of  special  interest,  because  economic  theory 
suggests, as will be argued below, an important impact of these factors. However, due to data 
limitations, empirical evidence is lacking or is insufficient.  
No empirical study so far includes physician quality as a potential factor for the decision for 
screening. The reason is that survey data including this information are scarce.
3 Physician 
quality can be expected to influence the decision for screening, since asymmetric information 
is particularly widespread in health care markets often forcing expert physicians to act on 
behalf of their less informed patients (e.g. McGuire 2000). Moreover, individual perception of 
risks is often biased (e.g. Viscusi 1990). Breast cancer is no exception in this regard and even 
women with a high risk of getting breast cancer tend to have false perceptions of the risks and 
the seriousness of breast cancer (Richards et al. 2010). For this reason, physicians often need 
to  act  as  agents  for  their  less-informed  patients,  and  they  play  an  important  role  in 
determining  mammography  screening  take-up.  Empirical  evidence  clearly  indicates  that 
women follow physician advice for mammography screening (e.g. May et al. 1999, Meissner 
et al. 2008). Thus, we hypothesize that a better physician – as measured by an index defined 
in  section  2  –  will  more  often  suggest  mammography  screening  in  line  with  the  official 
national and EU screening guidelines, thus inducing higher screening rates.  
 
A  second  focus  within  the  “Analysis  of  Screening  Determinants”  lies  on  the  impact  of 
subjective live expectancy on mammography screening. Economic theory suggests (Ehrlich, 
Chuma 1990, Khwaja 2001) that the motivation to invest in one’s own health should depend 
on the subjective life expectancy. Women who expect a longer life should be more inclined to 
invest in health in order to spend more years in good health than women expecting to live 
only for another few years. A corresponding phenomenon has been empirically detected for 
smoking behaviour in the US-context by Fang et al. (2007) who call it the "Mickey Mantle 
Effect".
4 However – as will be shown in section 3.2 – empirical analysis has to consider that 
stated life expectancy suffers from measurement error, leading to attenuation bias. Moreover 
                                                 
3 Maurer (2009) as well as Schmitz and Wübker (2010) used physician quality to explain influenza vaccination decision in 
Germany and Europe using the SHARE. We base our paper on the quality score introduced by Maurer (2009). 
4 The phenomenon is named after the legendary American baseball player Mickey Mantle who exhibited 
a very unhealthy behaviour because he expected to die at an early age because several of his family members died of a rare 
hereditary disease at a young age. 
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life expectancy may be endogenous for two reasons. The first reason is reverse causality: 
investment  in  health  increases  life  expectancy.  The  second  reason  is  omitted  variables:  a 
healthier  person,  ceteris  paribus,  expects  to  live  longer  and  thus  has  a  larger  return  to 
investments that increase quality of life in old age (Fang et al. 2007). We follow Fang et al. 
(2007)  and  apply  their  empirical  approach  to  mammography  take-up  and  control  for 
measurement error and endogeneity of the subjective life-expectancy through an IV-approach 
(compare section 3). 
 
The results of the “Analysis of Screening Determinants” show that better physician quality, 
better education, being married, being a “high user” of healthcare, younger age and better 
health  are  associated  with  higher  rates  of  screening  take-up.  Moreover  subjective  life 
expectancy strongly influences screening probability once the measurement error is controlled 
for. The results of the “Analysis of Country Differences” reveal that in countries with low 
screening rates (e.g. Denmark, Greece and Poland) a battery of reasons (low expected benefits 
of screening, perception that it is ”not usual”, a lack of information about this type of care, 
financial restrictions, time costs and access barriers) are significant predictors of not getting a 
mammogram. In contrast in countries with high screening rates such as the Netherlands only 
beliefs regarding the benefits (“not necessary”) and the cause “not usual to get this type of 
care” seem to be important screening barriers. The remainder of the paper is organized as 
follows: Section 2 provides some information on the data set and the theoretical and empirical 
screening determinants. Section 3 discusses the empirical strategy, while section 4 presents 
the results. Section 5 summarises the results and adds some concluding remarks. 
 
2 Data, Determinants of Mammography Screening and Variables 
 
2.1 Data 
We use data from the first (2004) and second (2006) wave of the Survey of Health, Ageing 
and Retirement in Europe (SHARE) to analyze the determinants of mammography screening. 
SHARE is a large representative micro data set of more than 30 000 individuals above the age 
of  50  years  from  14  European  countries  and  Israel  starting  in  2004.  It  provides  detailed 
information on health status and on a variety of other socioeconomic characteristics. The data 
was collected using a computer assisted personal interviewing (CAPI) program, supplemented   7 
by  a  self-completion  paper  and  pencil  questionnaire.
5  The  pencil  questionnaire  (“drop-off 
questionnaire”) includes a question about mammography take-up in the last two years. This 
questionnaire was only sent to a subgroup of the sample and no respondent received it in both 
waves.  
 
We restrict our sample to women aged 50-69, since for this group mammography screening is 
officially  recommended  at  both  European  level  and  the  national  level  of  the  countries 
included. Moreover, we exclude women if they reported a history of cancer as they are not 
representative and we discard observations with missing or unreliable values for the variables 
of interest and the other explanatory variables. Therefore, our estimation sample consists of 
two cross-sections with 6893 women in total (4412 from the first wave surveyed in 2004 and 
2481 from the second wave surveyed in 2006).  
To get a deeper understanding of the causes of not undergoing mammography screening and 
in the causes for differences in country-specific screening rates we analyse newly available 
data from the third wave (2009) of the SHARE (“SHARELIFE”). SHARELIFE focuses on 
people's  life  histories.  The  SHARELIFE  questionnaire  contains  detailed  information  on 
historical mammography screening use and provides evidence on the reasons why women did 
not  regularly  take-up  mammography  screening.  This  additional  sample  consists  of  4595 
women.  Table  1  provides  descriptive  statistics  of  the  variables  included  in  the  empirical 
analysis.  
                                                 
5 For more details on the sampling procedure, questionnaire contents and fieldwork methodology, readers should refer to 
Börsch-Supan and Jürges (2005).   8 
Table 1: Sample Means and Description 
Variable  Definition  Mean (N=6893) 
Variables from Wave 1 and 2 of the SHARE   
Dependent Variable     
Mammogram  Mammogram screening in the last two years (Yes=1, No=0)  0.647 
Explanatory Variables     
Physician Quality Index  GP quality between 0 and 1 as explained in the text  0.301 
Life Expectancy  Self-stated probability of being alive in about 10 years   0.670 
50 ≤ Age < 55    0.288 
55 ≤ Age < 60    0.273 
60 ≤ Age < 65    0.243 
65 ≤ Age < 70    0.195 
Self Assessed Health  Excellent=1 to poor = 5  2.907 
Limitations in ADL  Number of limitations in Activities of Daily Living   0.113 
Heart attack  Chronic Conditions: Heart attack  0.067 
Stroke  Chronic Conditions: Stroke  0.019 
Diabetes  Chronic Conditions: Diabetes  0.074 
Lung disease  Chronic Conditions: Lung Disease  0.041 
Has Partner  Binary Variable for whether to women has a partner  0.744 
Children in HH  Number of children living in household  0.462 
ISCED Low  Education ISCED
1 level between 0 and 2  0.444 
Doctor visits ≥ 10  Number of doctor visits ≥ 10 within the previous 12 month  0.221 
No drugs  Binary Variable for whether the woman regularly takes prescription drugs  0.314 
Hospital Stays ≥ 2  Number of hospital stays ≥ 2 within the previous 12 month   
Country and year dummies     
Year 2006    0.361 
Austria    0.079 
Germany    0.098 
Sweden    0.068 
Netherlands    0.088 
Spain    0.068 
Italy    0.093 
France    0.071 
Greece    0.044 
Switzerland    0.059 
Belgium    0.099 
Czech    0.068 
Poland    0.068 
Ireland    0.038 
Denmark    0.059 
Instruments     
Father Age at Death ≤ 65    0.262 
Father Age at Death 65 to 69    0.111 
Father Age at Death 70 to 74    0.111 
Father Age at Death 75 to 79    0.126 
Father Age at Death 80 to 84    0.139 
Father Age at Death ≥ 85    0.093 
Age Father_IV  Age at death or current age of father if still alive  72.02 
Mother Age at Death ≤ 65    0.144 
Mother Age at Death 65 to 69    0.070 
Mother Age at Death 70 to 74    0.092 
Mother Age at Death 75 to 79    0.116 
Mother Age at Death 80 to 84    0.125 
Mother Age at Death ≥ 85    0.118 
Age Mother_IV  Age at death or current age of mother if still alive   
Variables from the SHARELIFE - Questionnaire  (N= 4595) 
Not Affordable  Not affordable  0.023 
Not Covered  Not covered by health insurance  0.010 
No Insurance  Did not have health insurance  0.003 
Time Constraints  Time constraints  0.043 
No Information  Not enough information about this type of care  0.091 
Not Usual  Not usual to get this type of care  0.143 
Not Necessary  Not considered to be necessary   0.659 
Not Available  No place to receive this type of care close to home  0.025 
1International Standard Classification of Education   
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2.2 Determinants of Mammography Screening and Variables 
Economic theory suggests all variables mentioned in Table 1 could be important determinants 
of  individual  screening  decision.  From  an  economic  perspective  the  decision  to  undergo 
mammography screening is an investment decision. Such an investment is worthwhile if the 
expected present value of the reduction in disease and in the probability of death is larger than 
the opportunity costs of the intervention (comp. Grossman 1972, Cropper 1977, Dardanoni 
and  Wagstaff  1990  or  Chang  1996  for  a  formalization  of  these  notions).  However,  the 
question whether people actually decide to invest in mammography screening is largely an 
empirical one as we will argue in the following paragraphs. The paragraphs discuss certain 
hypotheses that would seem to be implied by economic theory and relate them to existing 
empirical results. Moreover the paragraphs describe the variables that we use in the empirical 
analysis in order to test the hypotheses.  
 
Age 
First of all, according to economic theory, age should influence mammography screening 
decision but the theoretical impact is offsetting. According to health human capital models 
(based on Grossman 1972) health depreciates at an increasing rate as one gets older, reducing 
the returns on investment. Moreover, the potential years of life saved due to mammography 
screening decline with age (Cropper 1997). Alternatively, older women should be more likely 
to take up mammography screening, because they have a greater risk for breast cancer than 
younger women (e.g. Grunfeld, Hunter Ramirez, Richards 2003) and thus expected benefits to 
mammography screening should be higher for those at higher risk for breast cancer. The great 
majority of empirical studies however indicate that older women are less likely to engage in 
mammography  screening  (e.g.  Wu  2003,  Kenkel  1994).  To  account  for  age  we  include 
dummy variables of different age groups.  
 
Health Status 
Health Status should also be associated with the decision for screening. Those in poorer health 
should be more likely to undergo mammography screening, since they potentially have higher 
cost to getting other diseases. For example rehabilitation and treatment may be more difficult 
for people in poor health than for those who are otherwise in good health (Nordin et al. 2002). 
Alternatively, it may be the case that people in poor health have less time to receive treatment 
or screens given their physical limitations. Furthermore women – as well as the physician   10 
acting as their agent (McGuire 2000)
6 – could set priority on other medical measures when 
sick, since mammography is associated with a future related and uncertain benefit (Gøtzsche 
and Nielsen 2009). Overall, it remains largely an empirical question whether poor health is 
associated  with  more  or  less  mammography  screening.  The  empirical  literature  is 
inconclusive  whether  poor  health  is  a  barrier  to  screening.  To  address  this  question,  we 
control for health using a detailed set of health indicators. These include self-assessed health 
(i.e. excellent, very good, good, fair, or poor), as well as a number of objective measures such 
as binary indicators for whether the respondent was ever diagnosed with stroke, heart disease, 
lung  disease  and  diabetes  as  well  as  an  index  of  limitations  in  activities  of  daily  living 
(ADLs).
7 ADLs refer to daily self-care activities within an individual's place of residence, in 
outdoor environments, or both.  
 
Education and Cognitive abilities 
Better  education  may  increase  the  use  of  screening  services,  implying  more  efficiency  in 
producing health (e.g. Grossman 1972). For example, a better educated woman may be more 
likely to understand the benefits of mammography screening. In addition, these women may 
be more prone to recognize the early warning signs of breast cancer and be more apt to visit a 
physician when symptoms first occur. Education is captured by a dummy variable for low 
education as defined by ISCED equivalents.
8 Since educational attainment in the past might 
not fully mirror the current skills to process information (Avitabile et al., 2008), we also 
analyse the role of current cognitive abilities captured by the variables “recall” and “verbal 
fluency”. Verbal fluency is measured by the number of different animals the respondent is 
able to state within one minute. Recall is measured by the number of words the respondent 
can  recall  from  a  list  of  ten  words  that  has  been  shown  her  some  minutes  before.  Both 
measures  reflect  cognitive  functions  as  identified  by  the  cognitive  psychology  literature 
(Richards  et  al.,  2004).  Empirical  studies  (e.g.  Mehta  et  al.  2010)  find  that  cognitive 
impairment is associated
 with lower screening mammography rates. We hypothesise that the 
                                                 
6 For example Yaskaskas et al. (2010) show that women with disabilities are less likely than those without disabilities to 
receive a physician recommendation for screening mammography. 
7 This variable describes the number of limitations with activities of daily living (ADL). Six activities are included: Dressing, 
including putting on shoes and socks, Walking across a room, Bathing or showering, Eating, such as cutting up your food, 
Getting in and out of bed, using the toilet, including getting up or down. 
8 The International Standard Classification of Education (ISCED) was designed by UNESCO in the early 1970`s to serve as a 
tool  to  facilitate  comparisons  of  education  statistics  and  indicators  of  different  countries  on  the  basis  of  uniform  and 
internationally agreed definitions. The higher the ISCED value the higher the education-level. The levels are as follows 
defined:  Level  0: Pre-primary  education;  Level  1:  Primary  education  or  first  stage  of  basic  education;  Level  2:  Lower 
secondary or second stage of basic education; Level 3: (Upper) secondary education; Level 4: Post-secondary non-tertiary 
education; Level 5: First stage of tertiary education (not leading directly to an advanced research qualification); Level 6: 
Second stage of tertiary education (leading to an advanced research qualification, e.g. a Ph.D.). We define low education by 
ISCED values between 0 and 2.  
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worse the cognitive skills the lower the probability to screen, since cognitive impairments 
limit the patients’ ability to gather and process information.  
By increasing the actual or perceived costs of processing information, they can act as a barrier 
for  mammography  screening.  The  positive  influence  of  information  on  the  demand  of 
prevention  is  shown  by  Parente  et  al.  (2004),  who  find  that  consumer  knowledge  has  a 
substantial positive effect on the use of preventive services. 
 
Family Structure 
Having a partner should be associated with higher screening rates as empirical studies reveal 
(e.g. Coughlin et al. 2008, Mehta et al. 2010). Those who have a partner and/or have children 
are probably reminded more often of the importance of mammography by their loved ones. 
Thus living not alone should lower information costs. We include controls for the number of 
children living in the household and a dichotomous variable for whether a woman has partner.  
 
High Users  
Another factor for the screening decision should be how much prior health care one has used. 
Some individuals are simply “high users” of medical care, while others may choose not to 
utilize health care, even when it is readily available and affordable. Wu (2003) finds empirical 
evidence for this regarding mammography screening in the US-context. To address “using 
behaviour”  in  the  European  context,  we  follow  the  empirical  strategy  of  Wu  (2003)  and 
include three dichotomous variables for whether a women i) had at least ten doctor’s office 
visits in the last year, ii) more than two hospital stays in the last year and iii) regularly takes 
prescription drugs. 
 
Financial Restrictions, Time Costs and Availability of Care Close to Home 
According to health human capital models (Grossman 1972) financial barriers should have a 
negative effect on the demand for mammography screening. Indeed empirical studies find that 
insurance coverage of breast cancer screening – which reduces the price of care at the point of 
service  –  inreases  the  probability  of  getting  mammography  screening  (e.g.  Kenkel,  1994, 
Lairson et al. 2005). Moreover empirical studies (e.g. Piccone et al. 2004, Lairson et al. 2005) 
suggest  a  positive  impact  of  higher  income  on  screening  probability,  since  high  income 
increases the ability to purchase services. Furthermore, economic theory implies a negative 
influence of higher time costs on health care utilization (e.g. Acton 1975). The only empirical 
study considering time costs (Lairson et al. 2005) reveals that for women veterans in the   12 
United States waiting time is inversely related to the likelihood of mammography screening. 
Finally – as it even lowers time costs of screening –, availability of mammography screening 
service  close  to  home  seems  to  be  an  important  determinant  for  getting  a  mammogram 
(compare Coughlin et al. 2008 for empirical evidence). 
 
We address the role of financial restrictions, availability of care close to home and time costs 
in  a  separate  analysis  in  section  4  using  the  SHARELIFE.  More  Precisely,  SHARELIFE 
includes the question “Have you ever had mammograms regularly over the course of several 
years?” If the women answered “No” the SHARELIFE continues “What are the reasons you 
[have never had/stopped having] mammograms regularly?” providing the response-options 
“1. Not affordable “2. Not covered by health insurance”, “3. Did not have health insurance”, 
“4. Time constraints”, “5. Not enough information about this type of care” “6. Not usual to 
get  this  type  of  care”  “7.  No  place  to  receive  this  type  of  care  close  to  home”,  “8.  Not 
considered to be necessary”, “9. Other reasons”. We construct for each response-option a 
binary variable and analyse in section 4 the magnitude of each response option in explaining 
the decision not to undergo a mammogram. 
  
Life Expectancy 
The motivation to invest in one’s own health should depend on the subjective life expectancy 
of the respondent as well. Individuals who expect a longer life should be more inclined to 
invest in health, since the potential payoff of health investments is greater for people in good 
health than for people who believe to live for a few more years only (Ehrlich and Chuma 
1990). Fang et al. (2007) find that individuals who expect a longer life are significantly less 
likely to be currently smoking. They find no effect, however, for other health behaviours like 
heavy drinking or obesity. We calculate a variable indicating subjective life expectancy from 
following  question  of  the  SHARE:  What  are  the  chances  that  you  will  live  to  be  age 
75/80/85/90/95/100/105/110/120 or more?" (either 75 or current age plus about 10 years, see, 
e.g., Hurd and McGarry (2002) for a discussion on the reasonability of this measure).  
 
Physician Quality 
Finally,  we  want  to  analyse  the  impact  of  physician  quality  on  the  decision  to  undergo 
mammography screening. As argued by Maurer (2009), health literacy of the typical patient is 
limited,  and  patients  rely  heavily  on  their  physician’s  advice.  Usually,  they  follow  their 
doctor’s recommendation, which also applies to mammography screening. May et al. (1999)   13 
find in an US-study that 66 percent of women who received a recommendation adhered and of 
women receiving a documented recommendation, 75 percent adhered. Alternatively Meissner 
et al. (2008) found for the US that 80 percent of non-screeners who reported having access to 
healthcare did not receive a recommendation for a mammogram.  
Unfortunately, we cannot test directly for the impact of physician’s advice on the probability 
of screening decision. We therefore follow Maurer (2009) as well as Schmitz and Wübker 
(2011) and compute a physician quality score and assume that better physicians are more 
likely  to  recommend  mammography  screening.
9  The  quality  score  is  computed  in  the 
following  way.  We  use  the  answers  of  individuals  to  five  questions  in  the  drop-off 
questionnaire concerning specific geriatric assessments, which any general practitioner should 
routinely  perform.  These  are  how  frequently  a  doctor  i)  asks  about  physical  exercise,  ii) 
suggests regular physical exercise, iii) asks about falls, iv) checks balance, and v) asks about 
drugs used. We sum up all the answers where we assign the category "at every visit" a 2, "at 
some visits" a 1 and "never" a 0. Like Maurer (2009) and Schmitz and Wübker (2011) we 
acknowledge that some questions are the more important the older the women are and the less 
important the younger the women are. Therefore, we do not consider balance checks and 
queries about falls if the respondent is aged 50-59. For women aged 60-69 we weight the 
answers to these two questions with 0.5. To get a quality indicator that falls into the range of 0 
and 1 we divide the sum by the age-adjusted maximum possible number of points. 
 
3. Empirical Strategy and Estimation Results  
3.1. Basic Analysis 
We apply two basic regression models: First the linear probability model, that is, an OLS-
regression  of  the  variable  indicating  a  mammography  screening  on  the  above-mentioned 
exogenous variables.
10 Second the probit regression model, which in contrast to the OLS-
regression imposes the restriction that a predicted value lies inside the range of [0,1]. To 
control for institutional and cultural differences in screening behaviour we include a full set of 
                                                 
9 The indicator used by Schmitz and Wübker (2011) differs slightly from the one that Maurer (2009) uses. The reason is, 
firstly, that one question ("How often does your GP check your weight?") is only asked in the first wave. Schmitz and 
Wübker (2011) ignore this one and use only five instead of six questions. Furthermore, Maurer does not weight the answers 
but assigns a 1 if the GP asked a specific question during at least some visits. The pros and cons of this approach can be 
debated. On the one hand, Maurer’s method comes with an information loss. On the other hand, his approach might be more 
robust to recall error as it is easier to remember if a GP ever asked this question than how regular she does. However, we 
tried both quality scores and did not find qualitative differences in our results. Moreover we tested analogue to Schmitz and 
Wübker (2011) different weighting schemes of the questions in order to test robustness of the results. We find only small 
differences in our results. The results are available upon request.  
10 It turns out that less than 1 percent (55 observations) of all observations have a predicted value outside the range of [0, 1]. 
We feel that this is a reasonably low figure.   14 
country  dummies.  Table  2  reports  the  results  of  the  linear  probability  model  in  the  first 
column.  
 
Table 2: Estimation Results from OLS and Probit 
  (OLS)    (Probit)   
  Mammogram    Mammogram   
Physician Quality Index  0.107
**  (0.041)  0.116
***  (0.042) 
Life Expectancy  0.065
**  (0.030)  0.072
**  (0.031) 
55 <= Age < 60 (d)  0.015  (0.015)  0.020  (0.018) 
60 <= Age < 65 (d)  0.005  (0.013)  0.007  (0.015) 
65 <= Age < 70 (d)  -0.095
**  (0.032)  -0.102
***  (0.035) 
Self Assessed Health  -0.009
**  (0.004)  -0.011
**  (0.005) 
Number of ADL  -0.029
**  (0.011)  -0.032
***  (0.012) 
Heart attack (d)  -0.020  (0.021)  -0.023  (0.024) 
Stroke (d)  -0.083
**  (0.031)  -0.099
***  (0.036) 
Diabetes (d)  -0.055
**  (0.019)  -0.063
***  (0.021) 
Lung disease (d)  0.012  (0.025)  0.010  (0.030) 
ISCED Low (d)  -0.056
**  (0.020)  -0.066
***  (0.021) 
Verbal Fluency  0.002
*  (0.001)  0.003
**  (0.001) 
Recall Delayed  0.001  (0.004)  0.000  (0.004) 
Has Partner (d)  0.046
***  (0.014)  0.053
***  (0.016) 
children_hh  -0.008  (0.013)  -0.009  (0.014) 
Doctor visits = 10 (d)  0.041
**  (0.016)  0.046
***  (0.018) 
Regularly Drugs (d)  0.055
***  (0.010)  0.064
***  (0.011) 
Hospital Stays = 2 (d)  0.019  (0.047)  0.016  (0.051) 
Year 2006  0.006  (0.010)  0.007  (0.013) 
Austria (d)  0.477
***  (0.009)  0.318
***  (0.004) 
Germany (d)  0.251
***  (0.006)  0.209
***  (0.004) 
Sweden (d)  0.634
***  (0.008)  0.365
***  (0.001) 
Netherlands (d)  0.645
***  (0.011)  0.378
***  (0.002) 
Spain (d)  0.470
***  (0.021)  0.312
***  (0.007) 
Italy (d)  0.452
***  (0.018)  0.314
***  (0.008) 
France (d)  0.614
***  (0.010)  0.362
***  (0.002) 
Greece (d)  0.225
***  (0.020)  0.191
***  (0.014) 
Switzerland (d)  0.271
***  (0.010)  0.217
***  (0.007) 
Belgium (d)  0.538
***  (0.009)  0.349
***  (0.003) 
Czech (d)  0.343
***  (0.021)  0.257
***  (0.012) 
Poland (d)  0.238
***  (0.025)  0.200
***  (0.018) 
Ireland (d)  0.285
***  (0.023)  0.224
***  (0.015) 
Observations  6893    6893   
Marginal effects; Standard errors in parentheses;  (d) for discrete change of dummy variable from 0 to 1 
* p < 0.10, 
** p < 0.05, 
*** p < 0.01 
 
The  results  indicate  that  physician  quality  has  a  positive  and  significant  impact  on  the 
decision to undergo mammography screening.
11 Specifically, our estimates show on average 
10.4  percentage  points  higher  screening  rates  among  women  whose  family  physician 
performs  all  geriatric  assessments  relative  to  those  whose  doctor  does  not  undertake  any 
                                                 
11 This basic result holds independently of the refinement of the physician quality measure.   15 
evaluation.
12 Given that the average screening rate in this age-group is 64 per cent, this is a 
considerable amount.  
Besides  physician  quality,  the  main  variable  explaining  the  demand  for  mammography 
screening is age. Older women are less likely to get mammograms. In example, being in the 
65–69  age  group  decreases  the  probability  of  getting  a  mammography  screening  by  9.5 
percentages points compared with the 50–54 age group. Generally, sicker women as measured 
by objective and subjective measures of health status are less likely to get mammograms. 
More precisely, lower ability to perform activities of daily living and suffering from chronic 
conditions  like  a  stroke  and  diabetes  are  similarly  associated  with  lower  screening  rates. 
Moreover, even after controlling for those objective measures of health status, worse self 
assessed health is associated with lower mammography screening rates. Education and the 
capability  of  processing  information  affect  the  mammography  screening  decision.  Both 
having a higher than low education and yielding more points in the verbal fluency test are 
associated with higher screening rates. The number of children in the household does not 
seem  to  play  an  important  role,  whereas  whether  a  woman  has  a  partner  significantly 
increases the screening probability.  
Being “high-users” of medical care is significantly positive associated with mammography 
screening. Specifically, our estimates show on average 5.5 percentage points higher screening 
rates among women who regularly take drugs compared to women who do not take drugs 
regularly. Moreover, women who had at least ten doctor visits in the last year have on average 
4 percentage points higher screening rates than those with less than ten doctor visits.   
Finally, higher subjective life-expectancy significantly increases the likelihood of getting a 
mammogram.  A  10  percentage  point  increase  in  subjective  life  expectancy  reduces 
probability of mammography screening by about 0.6 percentage points. The results for the 
probit estimation are quite similar to those of the OLS estimation for most variables as can be 
seen in the right column of Table 2. Noteworthy is, however, that the coefficient of physician 
quality and life expectancy are a little bit higher using probit specification compared to OLS. 
Moreover, we find significantly smaller differences in the coefficients of the country dummies 
in the probit estimates, since the probit model imposes the restriction that a predicted value 




                                                 
12 Alternatively, women who are treated by a physician with a one standard deviation higher quality score have roughly 3 
percentage points’ higher screening rates.     16 
3.2. Measurement error and endogeneity Concerns 
As stated in the introduction, we are seriously concerned that subjective life expectancy as 
one of our most important covariates suffers from measurement error leading to attenuation 
bias. Measurement error arises if an explanatory variable is measured with additive random 
errors. The higher the part of variability that is due to errors, the larger is the magnitude of the 
attenuation bias (e.g. Angrist and Kruger 2001). Hurd, McFadden and Gan (1998) reveal that 
due to cognitive disability a lot of respondents systematically provided focal-point answers (0, 
0.5  or  1)  to  the  questions  on  subjective  survival  probabilities  in  the  sample  of  older 
individuals (aged 70 and over) in the Study of Assets and Health Dynamics among the Oldest 
Old (AHEAD). A similar response pattern comes up for women aged 50-69 in the SHARE-
data with many focal answers at 0, 0,5 and 1 as shown by Figure 1. These cannot represent the 
true probabilities, both because the distribution of true probabilities should be continuous and 
because the true probabilities cannot be exactly either zero or one (Hurd, McFadden and Gan 
1998).  In  the  consequence  the  coefficient  on  that  variable  in  an  ordinary  least  squares 
regression will be biased towards zero. 
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Moreover,  following  the  discussion  of  Fang  et  al.  (2007)  the  impact  of  subjective  life 
expectancy on investment in health is endogenous, mainly due to reversed causality. While   17 
investment in health might depend on subjective life expectancy (which is to be analysed 
here), subjective life expectancy is also likely to depend on investment in health. Individuals 
who generally invest more in health might believe in a pay-off of their behaviour, resulting in 
the expectancy of a longer life. We follow Fang et al. (2007) and Bloom et al. (2006) in using 
age at death of respondents’ parents (or their current age if still alive), as well as age², age³ 
and binary indicators of whether the father or mother died at an age that fell in the range of 
under 65, 66 to 70, 71 to 75, 76 to 80, 81 to 85, or 86 and over.
13 The instruments can be seen 
as  proxies  for  health  endowment  like  genetic  factors  that  are  transfused  from  parents  to 
children. Individuals with older parents are likely to have a better health endowment than 
those whose parents died early, possibly due to a genetic disease.  
The identifying assumption here is that genetic factors affect subjective life-expectancy but 
not the decision to get a mammography screening once health and subjective life-expectancy 
are controlled for. According to our strategy in the “Basic-Analysis” section, we perform both 
linear Instrumental Variable Two-Stage Least Squares (IV-2SLS) estimation (following Fang 
et al. 2007), and a non-linear two-stage procedure following Newey (1987) to correct standard 
errors in the presence of a dichotomous dependent variable in the second stage. The 2SLS 
method is usually chosen even in cases where the dependent variable is dichotomous (e.g. 
Wooldridge 2002) since strong specification assumptions are required to justify the Newey 
(1987)  method.  We  present  both  for  completeness  and  find  quite  similar  results  with  all 
specifications.  
 
Table 3 reports the results of linear and non-linear two-stage procedure.
14 While the other 
coefficients remain quite stable when the instrumental variables regression is performed, the 







                                                 
13 Good instruments should show a considerable explanatory power for subjective life expectancy but must not affect the 
decision to undergo a mammography screening once the remaining explanatory variables are controlled for. 
14 Table A 1 in the Appendix reports the first-stage results from two-stage estimation. The dependent variable is self-stated 
probability of being alive in about 10 years.  Clearly, health status as measured by self assessed health is a very important 
determinant of life expectancy. Moreover, parents’ ages at death have large and significant effects in the expected direction. 
For instance, having a father who died between 65 and 69 years reduces the subjective probability of being alive in about 10 
years by 4.5 percentage points, ceteris paribus (compared to those women, whose father is still alive). The F-test for the joint 
significance of the parental age at death variables is 14.54 indicating that the instruments are not weak.  
15 Note, however that the coefficients measuring health status (e.g. Self Assessed Health) change in the IV-OLS compared to 
OLS. This is due to the correlation of the health measures with the instruments.    18 
Table 3: Estimation results from IV OLS and IV Probit model 
  (IV-OLS)    (IV-Probit Model)   
  Mammogram    Mammogram   
Second Stage Regression         
Physician Quality Index  0.108
***  (0.039)  0.115
***  (0.042) 
Life Expectancy  0.256
*  (0.131)  0.361
*  (0.203) 
55 <= Age < 60 (d)  0.012  (0.015)  0.015  (0.018) 
60 <= Age < 65 (d)  -0.001  (0.012)  -0.003  (0.015) 
65 <= Age < 70 (d)  -0.091
***  (0.031)  -0.094
***  (0.036) 
Self Assessed Health  0.000  (0.009)  0.004  (0.012) 
Number of ADL  -0.025
**  (0.011)  -0.025
**  (0.012) 
Heart attack (d)  -0.012  (0.019)  -0.009  (0.023) 
Stroke (d)  -0.083
**  (0.033)  -0.098
**  (0.041) 
Diabetes (d)  -0.048
***  (0.018)  -0.051
**  (0.022) 
Lung disease (d)  0.022  (0.027)  0.025  (0.031) 
ISCED Low (d)  -0.054
***  (0.020)  -0.061
***  (0.021) 
Verbal Fluency  0.002
*  (0.001)  0.002  (0.001) 
Recall Delayed  0.000  (0.004)  -0.001  (0.004) 
Has Partner (d)  0.046
***  (0.014)  0.052
***  (0.017) 
children_hh  -0.007  (0.012)  -0.008  (0.014) 
Doctor visits = 10 (d)  0.040
**  (0.016)  0.045
**  (0.018) 
Regularly Drugs (d)  0.057
***  (0.010)  0.065
***  (0.011) 
Hospital Stays = 2 (d)  0.022  (0.048)  0.020  (0.055) 
Year 2006  0.003  (0.009)  0.003  (0.013) 
Austria (d)  0.493
***  (0.016)  0.326
***  (0.006) 
Germany (d)  0.263
***  (0.011)  0.220
***  (0.007) 
Sweden (d)  0.644
***  (0.011)  0.368
***  (0.003) 
Netherlands (d)  0.649
***  (0.010)  0.379
***  (0.002) 
Spain (d)  0.466
***  (0.019)  0.309
***  (0.008) 
Italy (d)  0.453
***  (0.017)  0.313
***  (0.008) 
France (d)  0.622
***  (0.013)  0.365
***  (0.003) 
Greece (d)  0.236
***  (0.024)  0.200
***  (0.016) 
Switzerland (d)  0.277
***  (0.011)  0.221
***  (0.007) 
Belgium (d)  0.554
***  (0.016)  0.356
***  (0.006) 
Czech (d)  0.387
***  (0.036)  0.287
***  (0.022) 
Poland (d)  0.263
***  (0.031)  0.223
***  (0.022) 
Ireland (d)  0.296
***  (0.023)  0.231
***  (0.014) 
Observations  6893    6893   
F-Stat. instruments first stage  14.54       
Overid. Statistics²  27.15  (p = 0.101)       
Marginal effects; Standard errors in parentheses 
 (d) for discrete change of dummy variable from 0 to 1 
* p < 0.10, 
** p < 0.05, 
*** p < 0.01; ²p-values in parenthesis 
 
The  change  is  as  predicted.  It  indicates  that  the  effect  of  life  expectancy  is  strongly 
underestimated  when  measurement  error  and  endogeneity  is  not  taken  into  account. 
Subjective life expectation heavily increases the probability of investing in one’s own health 
(by  taking  a  mammogram).  Specifically,  the  estimates  imply  that  a  10  percentage  point 
increase  in  this  subjective  probability  reduces  probability  of  mammography  screening  by 
about 2.3 percentage points. This effect is much stronger than before (0.6 percentage points)   19 
and still significant on the 10 per cent level. Possibly, this effect is too high, since the large 
standard errors associated with the IV approach leads to large 90 percent confidence intervals 
of [0.0073438; 0.4492358]. However, this result does not seem to be due to weak instruments 
as the F-statistics exceeds the Staiger-Stock rule-of-thumb of 10 (Staiger and Stock, 1997) 
when testing for the exclusion of the instruments in the first-stage regression. Furthermore, 
over-identification tests support the validity of our instruments. If one is willing to assume 
that  the  mother’s  age  of  death  is  exogenous  to  the  individual  mammography  screening 
decision, the hypothesis that all other instruments are valid cannot be rejected. 
Again, most of the coefficients in the IV-Probit Model are quite similar to those of the IV-
OLS Model, as can be seen in the right column of Table 3. However, the impact of life 
expectancy is about 40 percent higher (0.361 versus 0.256) in the IV-Probit Model compared 
to the IV-OLS Model. Moreover, once more the coefficients of the country dummies in the 
IV-probit estimates are significantly smaller compared to the IV-OLS estimates. However in 
both  models  they  remain  always  jointly  significant  indicating  huge  differences  across 
countries that are not picked up by individual differences in our observed variables.
16   
 
4 Additional insights from the SHARELIFE 
 
4.1 Causes of not undergoing mammography screening in European countries 
To get a deeper understanding why women do not undergo mammography we analyse in 
addition data from the third wave of the SHARE (“SHARELIFE”). As described in the data 
section, the SHARELIFE directly asked women for the reasons why they did never had or 
stooped having mammograms regularly. The response options include the following answers: 
“1. Not affordable “2. Not covered by health insurance”, “3. Did not have health insurance”, 
“4. Time constraints”, “5. Not enough information about this type of care” “6. Not usual to 
get  this  type  of  care”  “7.  No  place  to  receive  this  type  of  care  close  to  home”,  “8.  Not 
considered to be necessary”. Out of a sample of 13491 women aged 50-69 years 4595 women 
never had or stopped having mammograms regularly.  
Table  4  presents  the  means,  the  standard  errors  (robust),  and  the  95  percent  confidence 
intervals of the different response options. “Not considered to be necessary” is by far the most 
important  reason  for  not  getting  a  mammogram.  Nearly  66  percent  of  women  state  this 
reason. Moreover many women mention “Not usual to get this type of care” (14 percent) and 
“Not enough information about this type of care” (9 percent) as reasons for not undertaking 
                                                 
16 Unfortunately there are no tests for a) weak instrument and b) over-identification of instruments in cluster-robust IV-Probit 
models.  However,  the  results  of  the  F-test  and  over  identification  test  in  the  linear  model  support  the  validity  of  our 
instruments and do not indicate that the robustness of the results suffer from weak instruments.     20 
mammograms. Roughly 4 percent of women refer to “Time constraints” and 2.5 percent state 
that is “No place to receive this type of care close to home”. Financial aspects like “Not 
affordable” (2.2 percent), “Not covered by health Insurance” (1 percent) and “Did not have 
health  insurance”  (0.1  percent)  did  play  a  minor  role  in  not  undergoing  mammography 
screening. However, except for “Did not have health insurance” each reason is significant at a 
5 percent level of significance.     
 
Table 4: Means, Standard Errors (robust) and 95 percent Confidence Intervals of the 
different response options 
 
  Mean  Robust Std. Error  95 % Conf. Interval 
Not Affordable  0.02285***     (0.00698)  [0.00763  ;  0.03807] 
Not Covered  0.01001***     (0.00352)  [0.00232  ;  0.0176] 
No Insurance  0.00152     (0.00101)  [-0.00068  ;  0.00373] 
Time Constraints  0.04265***     (0.01063)  [0.01948   ;  0.06582] 
No Information  0.09140***     (0.03672)  [0.01138   ;  0.17146] 
Not Usual  0.14276***     (0.03196)  [0.07311   ;  0.21241] 
Not Necessary  0.65897***     (0.04832)  [0.55369   ;  0.76426] 




*p<0.1, **p<0.05, ***p<0.01, standard errors in parentheses, clustered by countries. 
 
4.2 Differences between screening rates across European countries 
 
As  revealed  by  the  coefficients  of  the  country  dummies  in  Tables  2  and  3  there  remain 
considerable  differences  between  countries  in  screening  rates,  even  after  taking  several 
individual characteristics of women into account. Based on the first two waves (2004 and 
2006)  of  the  SHARE  data,  Figure  2  displays  the  enormous  differences  in  mammography 
screening rates across European countries. Whereas in Sweden almost 85 percent of women 
reported that they had received a mammogram in the past two years, only about 25 percent of 
Danish women reported that they got a mammogram. What accounts for the differences in 
mammography screening between the countries? To further explore this question, we analyse 
more deeply the above mentioned question from the SHARELIFE database. In a first step, we 
calculate for each response-option a dichotomous variable indicating the special reason for 
not undertaking mammography. In a second step we regress country dummies on all eight 
dichotomous variables (reflecting the different response options) and analyse whether there 
are  significant  differences  between  the  countries.  Table  5  presents  the  results  from  our 
regression analysis. 
   21 
Figure 2: Mammography Screening Rates in European countries 
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Table 5: Reasons for not getting mammograms in European countries 















































































































































































































































































N  4595  4595  4595  4595  4595  4595  4595  4595 
*p<0.1, **p<0.05, ***p<0.01, standard errors in parentheses, clustered by countries. 
 
The dummy coefficients reveal the percentage of women stating that the inquired aspect is 
relevant for their decision to not undertake regular mammography. In example – as can be   22 
seen in the left column of Table 5 – 3.5 percent of Austrian women who never had or stopped 
having mammograms regularly declare that mammograms in Austria were “not affordable” 
(Not Afford). Note, however that the question in the SHARELIFE only asked women who 
never had, or stopped having, mammograms regularly. To get percentage values that relate to 
all women in the country (i.e. women stating to get a mammogram as well as women not 
stating to get a mammogram), we have to adjust the values of the coefficients of each country-
dummy. More precisely, we multiply each dummy coefficient with the country-specific share 
of women who never had or stopped having mammograms regularly. For example, the 
coefficients for the dummies for the Netherlands (Germany) are multiplied by 0.25 (0.5), 
since in the Netherlands (Germany) 25 percent (50 percent) of women stopped or did not 
undergo a mammogram regularly. We present the adjusted values in Figure 2. 
 
Figure 3: Mammography Screening Barriers in European countries 
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The results in Figure 3 clearly show that “Not considered to be necessary” (Not Nec.) is the 
most important reason for not undergoing screening in most countries. However the actual 
impact differs significantly between the countries as shown in Figure 3 top right. Whereas in 
Denmark 51.6 percent of women mention this factor as a cause for not getting a mammogram, 
only 10 percent of women in Austria state this as a reason.  
Moreover “Not usual to get this type of care” (Not Usual) plays an important role in many 
countries (compare Figure 3 down right). Nearly 20 percent of women in Denmark state this 
as a reason. However in Sweden and the Netherlands this factor plays no significant role for 
not getting regular mammograms. “No information about this type of care” (No Info) is also 
relevant  in  many  countries  as  shown  in  Figure  3  top  left.  Specifically,  in  Greece  (18.5 
percent), Czech (7.7 percent) and Poland (5.3 percent) this factor plays an important role, but 
also in Germany (3.2 percent), Austria (3.5 percent), Spain (3.9 percent), Italy (2.3 percent) 
and Denmark (2.3 percent) having not enough information is relevant for not undergoing 
mammograms. In Figure 3 down left the variables “Not affordable”, “Not covered by health 
insurance” and “Did not have health insurance” are collapsed into the variable “Financial 
Restrictions”. Financial Restrictions are most important in Greece (4 percent), Germany (2.7 
percent) and Poland (1.9 percent). Time costs are mostly relevant in Austria (6.5 percent), 
Greece (5.1 percent)  and Poland (3.2 percent)  but also significant predictors in  Italy  (2.6 
percent),  Sweden  (2.2  percent),  Belgium  (1.6  percent),  Switzerland  (1.4  percent)  and 
Germany  (1  percent).  Finally  “No  place  to  receive  this  type  of  care  close  to  home”  is  a 
significant predictor for not receiving a mammogram in Greece (3.8 percent), Poland (5.2 
percent), Germany (1 percent) and Spain (1.4 percent). 
To summarize, there are enormous differences in mammography take-up between European 
countries, and the reasons for not undertake mammogram screening vary strongly between 
them. Whereas in all countries beliefs regarding the benefits (“not necessary”) seem to be 
important, only in some countries lack of information, financial restrictions, time costs and   24 
access play an important role in not receiving a mammogram. Generally in countries with 
high screening rates like the Netherlands, Sweden or France only some aspects seem to be 
relevant. In contrast, in countries with low screening rates (e.g. Denmark, Greece and Poland) 
many  reasons  are  significant  predictors  of  not  receiving  a  mammogram.  Since  “Not 
considered to be necessary” and “not usual get this type of care” are by far the most important 
factors,  further  research  is  necessary  to  explore  what  institutional  and  cultural  factors 
determine stating these reasons for not taking part in mammography screening.  
 
5. Discussion and Conclusion  
Breast  cancer  is  the  main  cause  of  cancer-mortality  among  women  in  Europe.  Screening 
mammography helps to detect breast cancer before it becomes invasive, and mortality can be 
significantly reduced by regularly mammography screening. Moreover, for women aged 50-
69  mammography  screening  has  proven  to  be  highly  cost-effective.  Even  though 
mammography is officially recommended both on the national and European level for this 
group of women, screening rates in most European countries remain far from 100 percent and 
reasons for underparticipation remain unclear. One purpose of this paper was to conduct an  
empirical test of certain hypotheses implied by economic theory concerning the determinants 
of  mammography  screening  focusing  on  European  women  aged  50-69  using  the  SHARE 
data-base  (“Analysis  of  Screening  Determinants”).  Moreover,  as  there  are  enormous 
differences  in  mammography  screening  rates  between  the  European  countries,  this  paper 
explored the causes of these country differences (“Analysis of Screening Differences”) using 
data from the third wave of the SHARE (“SHARELIFE”).  
The results of the “Analysis of Screening Determinants” indicate that better education, being 
married, younger age and better health consistently associated with higher rates of screening 
take-up. These results suggest that additional efforts may be needed to inform and convince 
the women living alone but also the elderly  and women in poor health of the preventive 
benefits  of  mammography.  Certain  interventions  such  as  invitations  appointments  and 
telephone calls have shown to be effective at increasing uptake (comp. Jepson et al. 2000).  
The impact of physician quality and subjective life-expectancy was of special interest within 
the “Analysis of Screening Determinants”. Having a family physician who generally complies 
with  indicated  geriatric  assessments  –  as  a  proxy  for  physician  quality  –  has  a  strongly 
significant positive effect on mammography screening propensity. Specifically, our estimates 
indicate on average 10.7 percentage points higher screening rates among respondents whose 
family physician performs all geriatric assessments relative to those whose doctor does not 
undertake any evaluation.    25 
This result may imply that interventions could address the physicians as key communicator 
since the percentage of physicians who recommend mammography screening in Europe may 
be too low. In example, a study from Switzerland reveals (compare Keller et al. 2001) that 
among  clinically  practising  physicians,  only  22  per  cent  reported  generally  prescribing 
biannual screening mammography’s for women aged 50–69. Thus, there might be a need to 
educate physicians regarding the preventive benefits of mammography screening. Moreover 
we  find  that  the  impact  of  subjective  life-expectancy  on  screening  decision  substantially 
increases after taking measurement error and endogeneity into account. Women who expect a 
longer life are much more inclined to invest in mammography screening than women who 
believe to live a few more years only.  
 
Finally, the results of the “Analysis of Country Differences” reveal that in countries with low 
screening  rates  (e.g.  Denmark,  Greece  and  Poland)  many  reasons  (perceived  benefits  of 
screening,  “not  usual”,  lack  of  information,  financial  restrictions,  time  costs  and  access 
barriers) are significant predictors of not receiving a mammogram. In contrast in countries 
with  high  screening  rates  like  the  Netherlands  only  beliefs  regarding  the  benefits  (“not 
necessary”) and the cause “not usual to get this type of care” seem to be important screening 
barriers. These results suggest that in countries with generally low screening rates a bundle of 
measures addressing all these reasons might be necessary to improve screening participation 
whereas  in  countries  with  high  screening  rates  only  selective  measures  like  national 
promotions  of  mammography  screening  may  be  important  to  further  enhance  screening 
participation. Future research might investigate institutional and differences such as different 
national  promotions  of  mammography  screening,  different  access  to  physicians,  different 
information strategies or other cultural differences in order to explore further the remarkable 
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Appendix 
Table A1: First-Stage IV Regression Results: Predicting Life Expectancy  
  Dependent variable: Life Expectancy  
i.e. Self-stated probability of being alive in 
about 10 years  
Physician Quality Index  -0.002  (0.013) 
55 <= Age < 60  0.010  (0.008) 
60 <= Age < 65  0.021
*  (0.010) 
65 <= Age < 70  -0.031
***  (0.010) 
Self Assessed Health  -0.051
***  (0.004) 
Number of ADL  -0.020
**  (0.009) 
Heart attack  -0.041
***  (0.013) 
Stroke  0.002  (0.026) 
Diabetes  -0.030
***  (0.009) 
Lung disease  -0.052
***  (0.016) 
ISCED Low  -0.009  (0.009) 
Verbal Fluency  0.002
***  (0.001) 
Recall Delayed  0.003  (0.002) 
Has Partner  -0.000  (0.008) 
children_hh  -0.006  (0.004) 
Doctor visits = 10  0.004  (0.008) 
Regularly Drugs  -0.007  (0.006) 
Hospital Stays = 2  -0.013  (0.017) 
Year 2006  0.014
***  (0.004) 
Austria  -0.084
***  (0.003) 
Germany  -0.062
***  (0.003) 
Sweden  -0.057
***  (0.004) 
Netherlands  -0.023
***  (0.004) 
Spain  0.012
*  (0.006) 
Italy  -0.006  (0.006) 
France  -0.047
***  (0.003) 
Greece  -0.062
***  (0.006) 
Switzerland  -0.039
***  (0.004) 
Belgium  -0.083
***  (0.002) 
Czech  -0.218
***  (0.007) 
Poland  -0.133
***  (0.011) 
Ireland  -0.056
***  (0.010) 
Father Age at Death ≤ 65
++  -0.029  (0.018) 
Father Age at Death 65 to 69  -0.045
**  (0.015) 
Father Age at Death 70 to 74  0.001  (0.016) 
Father Age at Death 75 to 79  -0.007  (0.015) 
Father Age at Death 80 to 84  0.010  (0.008) 
Father Age at Death ≥ 85  -0.000  (0.015) 
Mother Age at Death ≤ 65
++  -0.032  (0.031) 
Mother Age at Death 65 to 69  -0.024  (0.015) 
Mother Age at Death 70 to 74  -0.015  (0.015) 
Mother Age at Death 75 to 79  0.014  (0.012) 
Mother Age at Death 80 to 84  -0.002  (0.013) 
Mother Age at Death ≥ 85  -0.014  (0.015) 
Age Father_IV
+++  0.005  (0.009) 
Age Father_IV²  -0.000  (0.000) 
Age Father_IV³  0.000  (0.000) 
Age Mother_IV
+++  -0.001  (0.010) 
Age Mother_IV²  -0.000  (0.000) 
Age Mother_IV³  0.000  (0.000) 
Constant  -26.179
***  (8.198) 
Observations  6893   
R-squared  0.161   
F-Test for excluded Instruments  14.54   
Standard errors in parentheses, clustered by countries.
 * p < 0.10, 
** p < 0.05, 
*** p < 0.01 
++ The omitted categories for the father and mother age at death dummies are mother still alive and father still alive.  
+++ Age in the age polynomials is either current age or age at death. 